Literature DB >> 12039856

Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein-capturing, viral J-domain.

Reinhold Schirmbeck1, Marcin Kwissa, Nicolas Fissolo, Shereen Elkholy, Petra Riedl, Jörg Reimann.   

Abstract

The N-terminal domain of large tumor antigens (T-Ag) of polyomaviruses forms a DnaJ-like structure with a conserved J domain that associates with constitutively expressed stress protein heat shock protein (hsp)73. Mutant (but not wild-type) SV40 T-Ag show stable, ATP-dependent binding to the stress protein hsp73 when expressed in cells from different vertebrate tissues. Intracellular T/hsp73 complexes accumulate to high steady-state levels. From this observation, we designed a vector system that supports stable expression of a large variety of hsp73-capturing, chimeric antigens containing an N-terminal, T-Ag-derived domain, and different C-terminal antigenic domains from unrelated antigens. Most antigenic domains tested could be stably expressed only in eukaryotic cells as fusion protein/hsp73 complexes. The N-terminal 77 residues representing the J domain of T-Ag were required for stable hsp73 binding and efficient expression of chimeric antigens. Hsp73-bound chimeric antigens expressed by DNA vaccines showed strikingly enhanced immunogenicity evident in humoral (antibody) and cellular cytolytic T lymphocytes (CTL) responses. The described system supports efficient expression of chimeric, polyvalent antigens and their codelivery with hsp73 as a "natural adjuvant" for enhanced immunogenicity for T and B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039856     DOI: 10.1096/fj.01-0993fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

1.  Different sources of "help" facilitate the antibody response to hepatitis D virus delta antigen.

Authors:  Peter Seizer; Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

2.  Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.

Authors:  Deyan Luo; Bing Ni; Peng Li; Wei Shi; Songle Zhang; Yue Han; Liwei Mao; Yangdong He; Yuzhang Wu; Xiliang Wang
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 3.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

Review 4.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

5.  Recombinant complexes of antigen with stress proteins are potent CD8 T-cell-stimulating immunogens.

Authors:  Andreas Wieland; Markus Denzel; Erika Schmidt; Stefan Kochanek; Florian Kreppel; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2008-06-13       Impact factor: 4.599

6.  Cloning and characterization of a ribosomal protein L23a from Haemaphysalis qinghaiensis eggs by immuno screening of a cDNA expression library.

Authors:  Jinliang Gao; Jianxun Luo; Youquan Li; Ruiquan Fan; Haiping Zhao; Guiquan Guan; Junlong Liu; Bettina Wiske; Chihiro Sugimoto; Hong Yin
Journal:  Exp Appl Acarol       Date:  2007-04-04       Impact factor: 2.380

7.  Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).

Authors:  Fahad N Almajhdi; Tilo Senger; Haitham M Amer; Lutz Gissmann; Peter Öhlschläger
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

8.  Endogenously Expressed Antigens Bind Mammalian RNA via Cationic Domains that Enhance Priming of Effector CD8 T Cells by DNA Vaccination.

Authors:  Jana Krieger; Petra Riedl; Katja Stifter; Gleyder Roman-Sosa; Thomas Seufferlein; Martin Wagner; Reinhold Schirmbeck
Journal:  Mol Ther       Date:  2019-01-22       Impact factor: 11.454

9.  IFN-γ treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.

Authors:  Katja Stifter; Jana Krieger; Leonie Ruths; Johann Gout; Medhanie Mulaw; Andre Lechel; Alexander Kleger; Thomas Seufferlein; Martin Wagner; Reinhold Schirmbeck
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.